Introduction: There are still MS has been diagnosed in Mongolia during last 40 years, there is a lack of information regarding to geographical distribution and ethnic differences in origins of MS. That is why our main purpose is to do study the prevalence rate of MS in populations of UB city. Goal: To determine the prevalence rate of MS in adult populations of Ulaanbaatar (UB) City.Materials and Methods: To study the morbidity of MS in Mongolia using statistical data; to determine the prevalence rate of MS using hospital-based design and following the “door-to-door” methods. Results: MS morbidity analysis of five-year statistical data (2003-2007) showed an average of 178 per 100000; morbidity level in both rural and urban settings was 7.0 per 100000; among them 43% were patients in the 30-40-year-old age group. According to our study the prevalence rate of MS in UB City for a adult population of 100,000 above the age of 16 was 10.3; Rate of prevalence in females is 4 times more than in males (15.8 vs 4.2); the highest prevalence rate in females was in the 40-49 year-old age group (31.3); in males was in the 50-59 year-old age group (14.9). It is shown by disease dominating middle-aged women and older men relatively (p<0.05). In our clinical study of 67 MS patients, the mean age was 41.79±8.76. The age at onset ranged from 18-50 years (31.5± 9.2-for females; 37.3± 9.7-for males). Conclusion: The average morbidity rate of MS in Mongolia by statistical analysis from 2003-2007 data was 7.0 per 100,000 people; with a female-to-male ratio of 2:1. The prevalence rate of MS in adult populations of Ulaanbaatar for 100,000 people was 10.3; with a “chi”-square for females that was 4 times higher compared to males.

Introduction: However MS having been diagnosed in Mongolia during the last 40-50 years, there are difficulties in its differential diagnoses from other demyelinating diseases. Therefore our main reasons are to do study the clinical characteristics of MS with comparison MRI findings.Goal. To determine the clinical characteristics of MS with correlations to MRI-findings using caseobserved methods.Materials and Methods: Used the “door-to-door” method to be find out and work with that 115 subjects, from which selected according to the diagnostics criteria 67 patients with following reexaminations for confirmation of diagnosis, during next 2 years these cases were studied with MRI and VEP to compare clinical manifestations, common forms by age and sex. 34 subjects for MRI and 6 patients for VEP examinations undergone respectively; SPSS-15.0 used to analyze collected materials; for description of the data used mean, median, standard deviation; to detect inter variable association used “t”-test, “Chi-square”, correlation coefficient; P-value for all significant cases.Results:Among sixty-seven MS patients the main clinical forms were cerebrospinal (55 patients – 82.1%), pure cerebral (4 patients–6.0%) and pure spinal–(8 patients–11.9%). Clinical course was relapsingremitting in 39 patients (58.2%); secondary-progressive in 12 patients (17.9%); progressiverelapsing in 13 patients (19.4%), and primary-progressive in 3 patients (4.5%). The most common location of first attacks was pyramid system–46,3%, visual pathway, predominantly causing damage to the optic nerve–43.3%, followed by the spinal cord - 37.3%, optic-spinal-20.9% and brainstem–10.3%. Pyramid, sensory and vision-dissociated symptoms were also reported in 77% of patients, and paroxysmal symptoms in 67% of patients. The MRI scan performed in 34 patients–50.7% determined dissemination-in-time 10(29.4%) and in-space 18(53%). On MRI scans in T2-weighted images, 16 hyperintense lesions within the periventricular white matter were found (56,3%); 3 lesions in area pons and cerebella (5,95%); 13 lesions in spinal cord white matter (30,4%) and 2 lesions in nervous opticus tract (7,45%). Conclusions: The main clinical forms were cerebrospinal (82%) and opticospinal, which formed more than half of the cases, in which relapsing-remitting (58%) and progressive-relapsing courses (19%) predominated. The relapsing and progressing course of the disease was directly determined by clinical symptoms and MRI scan findings of dissemination-in-time and in-space of existing lesions. As MS can be asymptomatic, it was found that MRI-findings were positive (11.8%) even when clinical manifestations disappeared.

OBJECTIVERNA interference was used to silence geranylgeranyltransferase Ⅰ(GGTase-Ⅰ) in vitro and to study the effect of GGTase-Ⅰ on the migration and invasion of tongue squamous cancer cells.

METHODSThree small interfering RNAs (siRNA) were designed according to the GGTase-Ⅰ sequence by Genebank and were transfected into tongue squamous cancer cells Cal-27 to knock down GGTase-Ⅰ expression. The tested cells were divided into three groups, as follows: the RNA-interfered groups (GGTase-Ⅰ siRNA1, GGTase-Ⅰ siRNA 2, GGTase-Ⅰ siRNA 3), a negative control group (disrupted by random sequence NC-siRNA), and a blank control group. GGTase-Ⅰ and RhoA gene expressions were examined by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. The optimum interference group was screened by qRT-PCR and Western blot and was assigned as the experimental group. Matrix metalloproteinase (MMP)-2 and MMP-9 protein expressions were examined by Western blot. GTP-RhoA expression of protein was examined by GST-pull down. The migration and invasion abilities were analyzed by wound healing assay and Transwell motility assay.

RESULTSGGTase-Ⅰ mRNA and protein expression in Cal-27 decreased significantly after transfection of GGTase-I siRNA (P<0.05). No significant difference of RhoA gene expression was detected. MMP-2, MMP-9, and GTP-RhoA protein expressions decreased significantly (P<0.05). The migration and invasion abilities were inhibited (P<0.05).

CONCLUSIONSTo inhibit GGTase-Ⅰ expression, the migration and invasion abilities of tongue squamous cancer cells should also be inhibited. Further studies on GGTase-Ⅰ may provide novel effective molecular targets for tongue squamous cancer cells.